Literature DB >> 24496047

The foregut theory as a possible mechanism of action for the remission of type 2 diabetes in low body mass index patients undergoing subtotal gastrectomy for gastric cancer.

Yeongkeun Kwon1, Abraham Abdemur2, Emanuele Lo Menzo2, Sungsoo Park3, Samuel Szomstein2, Raul J Rosenthal2.   

Abstract

BACKGROUND: The question of whether pure metabolic surgery could be used in nonobese patients with type 2 diabetes has been considered. The objective of this study was to assess the comparative effects of the Billroth I (BI) and Billroth II (BII) reconstruction methods on remission of type 2 diabetes in nonobese patients undergoing subtotal gastrectomy for cancer.
METHODS: The charts of 404 patients who underwent radical subtotal gastrectomy for cancer between January 2008 and December 2010 were retrospectively reviewed. From these patients, 49 with type 2 diabetes were included in this study. Diabetes remission rates, the percentage change in fasting plasma glucose levels, glycated hemoglobin levels, body mass index, and fasting total cholesterol levels at 2 years were observed. Outcomes were compared using propensity scores and inverse probability-weighting adjustment that reduced treatment-selection bias. Covariate-adjusted logistic regression models were assessed.
RESULTS: The 2-year diabetes remission rate for the 23 patients who underwent BI reconstruction was 39.1%, compared with 50.0% for the 26 patients who underwent BII reconstruction. At 2 years, the BII group showed lower glycated hemoglobin levels (BI, 6.4%; BII, 6.1%; P = .003) and had greater percent reductions in their average glycated hemoglobin levels from baseline (BI,-11.6%; BII,-14.5%; P = .043). BII reconstruction was significantly associated with an increased diabetes remission rate (odds ratio, 3.22; 95% confidence interval, 1.05-9.83) in covariate-adjusted logistic regression analysis.
CONCLUSIONS: These propensity score-adjusted analyses of patients who had undergone subtotal gastrectomy indicated that BII reconstruction was associated with increased diabetes remission compared with BI reconstruction during the 2-year follow-up period. This study suggests the possibility of employing the surgical duodenal switch for the treatment of nonobese type 2 diabetes patients.
© 2014 American Society for Bariatric Surgery Published by American Society for Metabolic and Bariatric Surgery All rights reserved.

Entities:  

Keywords:  Billroth; Gastric cancer; Metabolic surgery; Subtotal gastrectomy; Type 2 diabetes

Mesh:

Substances:

Year:  2013        PMID: 24496047     DOI: 10.1016/j.soard.2013.09.013

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  13 in total

1.  Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague-Dawley Rat Model.

Authors:  Ponnie R Dolo; Libin Yao; Chao Li; Xiaocheng Zhu; Linsen Shi; Jason Widjaja
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

2.  Impact of diabetes on prognosis of gastric cancer patients performed with gastrectomy.

Authors:  Xinhua Chen; Yuehong Chen; Tao Li; Luo Jun; Tian Lin; Yanfeng Hu; Huilin Huang; Hao Chen; Hao Liu; Tuanjie Li; Guoxin Li; Jiang Yu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

Review 3.  Metabolic syndrome and the hepatorenal reflex.

Authors:  Michael D Wider
Journal:  Surg Neurol Int       Date:  2016-11-15

4.  Improved glycemic control with proximal intestinal bypass and weight loss following gastrectomy in non-obese diabetic gastric cancer patients.

Authors:  Ali Guner; Minah Cho; Taeil Son; Hyoung-Il Kim; Sung Hoon Noh; Woo Jin Hyung
Journal:  Oncotarget       Date:  2017-11-01

5.  Long-term Follow-up for Type 2 Diabetes Mellitus after Gastrectomy in Non-morbidly Obese Patients with Gastric Cancer: the Legitimacy of Onco-metabolic Surgery.

Authors:  Tae-Hoon Lee; Chang Min Lee; Sungsoo Park; Do Hyun Jung; You Jin Jang; Jong-Han Kim; Seong-Heum Park; Young-Jae Mok
Journal:  J Gastric Cancer       Date:  2017-11-15       Impact factor: 3.720

Review 6.  Metabolic Surgery in Korea: What to Consider before Surgery.

Authors:  Mi Kyung Kim; Yoonseok Heo
Journal:  Endocrinol Metab (Seoul)       Date:  2017-09

7.  The long term effect of metabolic profile and microbiota status in early gastric cancer patients after subtotal gastrectomy.

Authors:  Xi-Hsuan Lin; Kuo-Hung Huang; Wei-Hung Chuang; Jiing-Chyuan Luo; Chung-Chi Lin; Po-Hsiang Ting; Shih-Hao Young; Wen-Liang Fang; Ming-Chih Hou; Fa-Yauh Lee
Journal:  PLoS One       Date:  2018-11-05       Impact factor: 3.240

8.  Remission of type 2 diabetes after gastrectomy for gastric cancer: diabetes prediction score.

Authors:  Yeongkeun Kwon; Jin-Won Kwon; Jane Ha; Dohyang Kim; Jaehyeong Cho; Soo Min Jeon; Shin-Hoo Park; Jinseub Hwang; Nam Hoon Kim; Sungsoo Park
Journal:  Gastric Cancer       Date:  2021-07-22       Impact factor: 7.370

Review 9.  Metabolic syndrome and the hepatorenal reflex.

Authors:  Michael D Wider
Journal:  Surg Neurol Int       Date:  2016-09-13

10.  Oncometabolic surgery: Emergence and legitimacy for investigation.

Authors:  Won Jun Kim; Yeongkeun Kwon; Chang Min Lee; Seung Hyun Lim; Yong Li; Junjiang Wang; Weixian Hu; Jiabin Zheng; Gang Zhao; Chunchao Zhu; Wei Wang; Wenjun Xiong; Quan Wang; Mingjie Xia; Sungsoo Park
Journal:  Chin J Cancer Res       Date:  2020-04       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.